Literature DB >> 10815787

Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea.

R Iyer1, R Baliga, R L Nagel, C Brugnara, K Kirchner, S Hogan, M H Steinberg.   

Abstract

Studies in adults with Hb SC disease suggested that hydroxyurea reduced hemolysis and increased red cell hydration. Because increased hydration should diminish the polymerization tendency of Hb S we hypothesized that hydroxyurea might repair the urine concentration defect of HbSC disease. Eight Hb SC disease patients, aged 10 to 17 years, were given hydroxyurea daily. Maximal urine concentrating ability following overnight fasting and after subcutaneous arginine vasopressin (dDAVP), blood counts, and cell volumes were observed for 12-15 months. All patients had impaired urine concentrating ability prior to hydroxyurea treatment and failed to increase their ability to concentrate urine following treatment (maximum urine concentration after an overnight fast and dDAVP, 520-530 mOsm). Mean corpuscular volume (MCV) and reticulocyte MCV increased after administration of hydroxyurea, and the reticulocyte count and ratio of red cell hemoglobin to reticulocyte hemoglobin fell but there was little change in PCV. Hb F increased substantially in 2 patients but showed little change in the remaining patients. There was no evidence that hydroxyurea was associated with increased urine concentrating ability in children with Hb SC disease. These results may reflect irreversible renal medullary damage prior to beginning treatment or insufficient intensity or duration of treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815787     DOI: 10.1002/(sici)1096-8652(200005)64:1<47::aid-ajh8>3.0.co;2-1

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Biomarkers for early detection of sickle nephropathy.

Authors:  Nambirajan Sundaram; Michael Bennett; Jamie Wilhelm; Mi-Ok Kim; George Atweh; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 2.  Knowledge insufficient: the management of haemoglobin SC disease.

Authors:  Lydia H Pecker; Beverly A Schaefer; Lori Luchtman-Jones
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

3.  Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).

Authors:  Scott T Miller; Winfred C Wang; Rathi Iyer; Sohail Rana; Peter Lane; Russell E Ware; Daner Li; Renée C Rees
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

4.  Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease.

Authors:  Carly C Ginter Summarell; Vivien A Sheehan
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-17

Review 5.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

6.  Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia.

Authors:  Jeffrey D Lebensburger; Rakeshkumar J Patel; Prasannalaxmi Palabindela; Christina J Bemrich-Stolz; Thomas H Howard; Lee M Hilliard
Journal:  J Blood Med       Date:  2015-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.